BMS to Acquire Mirati Therapeutics in a $4.8 Billion Deal
Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a definitive merger agreement with US-based oncology...
Mirati Therapeutics
Mirati Therapeutics Sues InventisBio Over Trade Secret Misappropriation
US-based Mirati Therapeutics (Nasdaq: MRTX) is reportedly suing China-based InventisBio Co., Ltd (SHA: 688382) over...